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Recessive inactivating mutations in the ABCC8 and KCNJ11 genes
encoding the adenosine triphosphate-sensitive potassium (KATP) channel
subunit sulphonylurea receptor 1 (SUR1) and inwardly rectifying
potassium channel subunit (Kir6.2) are the most common cause of
hyperinsulinaemic hypoglycaemia (HH). Most of these patients do not
respond to treatment with the KATP channel agonist diazoxide. Dominant
inactivating ABCC8 and KCNJ11 mutations are less frequent, but are
usually associated with a milder form of hypoglycaemia that is responsive
to diazoxide therapy. We studied ﬁve patients from four families with HH
who were unresponsive to diazoxide and required a near total
pancreatectomy. Mutations in KCNJ11 and ABCC8 were sought by
sequencing and dosage analysis. Three novel heterozygous ABCC8
mis-sense mutations (G1485E, D1506E and M1514K) were identiﬁed in
four probands. All the mutations affect residues located within the
Nucleotide Binding Domain 2 of the SUR1 subunit. Testing of family
members showed that the mutations had arisen de novo with dominant
inheritance in one pedigree. This study extends the clinical phenotype
associated with dominant KATP channel mutations to include severe
congenital HH requiring near total pancreatectomy in addition to a milder
form of diazoxide responsive hypoglycaemia. The identiﬁcation of
dominant vs recessive mutations does not predict clinical course but it is
important for estimating the risk of HH in future siblings and offspring.
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The pancreatic β-cell adenosine triphosphate-
sensitive potassium (KATP) channel is a complex
of four sulphonylurea receptor 1 (SUR1) with
four inwardly rectifying potassium channel sub-
units (Kir6.2) that play a pivotal role in regulating
insulin secretion (1). Metabolic regulation of KATP
channel activity is mediated by changes in the
intracellular concentrations of adenosine triphos-
phate (ATP) and MgADP, which inhibit or activate
the channel respectively (1, 2). Sulphonylureas and
diazoxide bind to the SUR1 subunits to, respec-
tively, close or open the channels independently of
ATP/adenosine diphosphate (ADP) concentrations
and stimulate or inhibit insulin secretion.
Hyperinsulinaemic hypoglycaemia (HH) is char-
acterized by the dysregulation of insulin secretion
that often presents in the neonatal period. Early
diagnosis is important to avoid irreversible brain
damage because of prolonged hypoglycaemia (3).
The clinical presentation is heterogeneous ranging
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from mild to severe symptoms of hypoglycaemia.
Inactivating mutations in the genes ABCC8 and
KCNJ11 encoding the SUR1 and Kir6.2 subunits
of the KATP channel are the most common cause
of HH (4, 5). Histologically, there are diffuse and
focal forms of the disease. Focal lesions arise from
paternal uniparental isodisomy of the chromosome
11p15 region within the embryonic pancreas of
a foetus with a paternally inherited KATP chan-
nel mutation (6). Surgical removal of the lesion is
usually curative. A similar number of cases have
recessively inherited the loss of function mutations
where the entire pancreas is affected (diffuse). This
usually leads to severe, medically unresponsive
HH often requiring a near total pancreatectomy.
The lack of response to diazoxide is believed to
be because of the absence of the KATP channels at
the membrane (if the mutation results in lack of
protein product or affects maturation/transport to
the membrane) or the presence of inactive KATP
channels that cannot respond to diazoxide.
Dominant inactivating mis-sense mutations in
ABCC8 and KCNJ11 are a rare cause of HH (7, 8).
To date the phenotype of patients with heterozy-
gous mutations seems to be different to those with
recessive mutations as they show responsiveness to
diazoxide. This response may be attributed to the
binding of diazoxide to a normal SUR1 subunit
within the heteromeric complex or to the presence
of a sufﬁcient proportion of normal KATP channels
as a consequence of the binomial distribution (9).
Huopio et al. described the ﬁrst dominantly inher-
ited ABCC8 mutation, E1507K (described by Huo-
pio et al. as E1506K based on isoform L78207 that
excludes the alternatively spliced amino acid in
exon 17), that caused HH in early life and predis-
poses to later insulin deﬁciency. All the patients
described in this large family had a mild form
of HH that could be managed by long-term dia-
zoxide treatment (7). Recently, Pinney et al. have
reported 14 different dominantly inherited ABCC8
or KCNJ11 mis-sense mutations in 16 families
with HH that often escaped detection in infancy
and responded to diazoxide (8). We now describe
ﬁve patients with heterozygous ABCC8 mutations
who presented with severe, medically unrespon-
sive HH and underwent near total pancreatectomy.
Materials and methods
Subjects
We studied ﬁve patients from four families with
HH. In one family, a mother and a son were
affected, whereas for the three remaining probands
there was no family history of HH. As a result
of the failure to respond to medical therapy, all
patients underwent a near total pancreatectomy.
This study was conducted in accordance with the
Declaration of Helsinki and informed consent was
obtained from all patients, with parental consent
given on behalf of children.
Molecular genetics
Genomic DNA was extracted from peripheral
leukocytes and pancreatic tissue using stan-
dard procedures and the single exon of the
KCNJ11 gene was sequenced as previously
described (10). When no KCNJ11 mutation was
identiﬁed, the 39 exons of ABCC8 were ampliﬁed
and sequenced (11). Sequences were compared to
the published sequence, NM_000352.2, that incor-
porates the alternatively spliced residue in exon
17 (L78208, L78224). Mutation testing was per-
formed on parental DNA extracted from peripheral
leukocytes. When a de novo mutation was identi-
ﬁed, microsatellite analysis conﬁrmed family rela-
tionships. In one family as the unaffected mater-
nal grandfather was deceased, haplotype analysis
was performed using six microsatellite markers on
chromosome 11p15 to determine the origin of the
mutation. Novel mutations were tested by sequenc-
ing 500 control chromosomes and dosage anal-
ysis of the ABCC8 gene was undertaken for all
probands (MRC Holland, Amsterdam, the Nether-
lands, multiplex ligation-dependent probe ampliﬁ-
cation kit P117). Pancreatic tissue was available
from two probands and loss of heterozygosity was
investigated by microsatellite analysis of chromo-
some 11p15 (12).
Histology/immunohistochemistry
Parafﬁn sections (3 μm thick) were cut from
blocks of resected pancreatic tissue from the four
probands and were stained with haematoxylin and
eosin (H & E). Immunostaining was performed
using polyclonal antibodies for insulin, somato-
statin, glucagon and pancreatic polypeptide as pre-
viously described (13). Pancreatic tissue was not
available from the mother of proband 2 who under-
went a pancreatectomy 23 years ago.
Results
Molecular genetics
Sequencing of the KCNJ11 gene failed to detect
any mutations but subsequent analysis of the
ABCC8 gene identiﬁed three different novel het-
erozygous mis-sense mutations in the ﬁve patients
(Table 1). The D1506E (c.4518C>A) mutation
was seen in three patients from two families.
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In family 1, testing of the unaffected parents
showed that the mutation had arisen de novo
in the proband. In family 2, the mutation had
been inherited from the affected mother. Testing
was undertaken for the unaffected maternal grand-
mother who did not carry the D1506E mutation.
No DNA was available from the deceased unaf-
fected grandfather, but haplotype analysis of chro-
mosome 11p15 markers suggested that the D1506E
mutation had arisen de novo on the grandmaternal
chromosome (Fig. 1). The G1485E (c.4454G>A)
and M1544K (c.4541T>A) mutations were each
identiﬁed in one patient. Testing of their unaffected
parents showed that the mutations had arisen de
novo. All three mutations affect highly conserved
residues within the Nucleotide Binding Domain 2
(NBD2) of SUR1, were not present in 500 nor-
mal control chromosomes and a second ABCC8
mutation was not detected by dosage analysis.
Analysis of markers on chromosome 11p15 in
DNA extracted from the resected pancreatic tis-
sue of probands from families 1 and 4 showed
biparental inheritance with no evidence for loss of
heterozygosity.
Histology/immunohistochemistry
Histological analysis of pancreatic material from
the four probands with dominant ABCC8 muta-
tions showed large giant endocrine nuclei in
scattered cells that stained positive for insulin anti-
bodies, which is not dissimilar to the changes
that are observed in patients with recessive
ABCC8 mutations (Table 1 and Fig. 2). Pancre-
atic polypeptide-positive cells were also observed
and immunostaining for somatostatin and glucagon
was unremarkable.
Clinical characteristics
All ﬁve patients presented with severe HH imme-
diately after birth and four patients were macro-
somic (birth weight >90th percentile; Table 1).
None responded to maximum doses of diazoxide
(20 mg/kg/day) and normoglycaemia could not be
maintained despite using high-calorie feeds and
octreotide. The probands from families 2 and 3
had a near total pancreatectomy at 8 weeks of
age and subsequently developed diabetes melli-
tus. Proband 4 and the mother of proband 2
underwent a near total pancreatectomy at 8 and
5 weeks of age, respectively, but post-operatively
they continued to have HH that was managed on a
combination of subcutaneous octreotide injections
and frequent high-calorie carbohydrates feeds.
Although proband 4 is still on treatment at the age
Fig. 1. Microsatellite analysis of markers spanning 15.5 Mb on
chromosome 11p15.5-15.1 in family 2 with hyperinsulinaemic
hypoglycaemia (HH) resulting from a heterozygous D1506E
mutation in the ABCC8 gene. ABCC8 is located between
markers D11S1981 and D11S902. Black bars indicate the
haplotype co-segregating with hyperinsulinism. Squares denote
males, circles females, and black symbols show individuals
affected with HH. Genotypes are provided below each symbol
and an arrow points to the proband.
of 3, the mother of proband 2 outgrew the HH at
11 years of age, but developed impaired glucose
tolerance at 14 years of age and required insulin at
23 years of age during her third trimester of preg-
nancy. Proband 1 underwent an initial near total
pancreatectomy but severe post-operative hypogly-
caemia required a second total pancreatectomy.
Despite this, the patient still requires continuous
high-calorie feeds and octreotide to maintain nor-
moglycaemia (Table 1).
Discussion
We identiﬁed three novel heterozygous ABCC8
mis-sense mutations (G1485E, D1506E and
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Fig. 2. (a and b) Comparison of the histology of the resected pancreas from the proband of family 2 and a patient with recessively
inherited congenital hyperinsulinism because of ABCC8 mutations. (a) Haematoxylin & eosin (H & E)-stained sections showing the
presence of scattered endocrine cells with large and frequently giant endocrine nuclei. The endocrine tissue was poorly organized
into islets. (b) H & E-stained sections of pancreatic tissue from a patient with recessive ABCC8 mutations showing the large and
frequently giant endocrine nuclei and irregularly sized islets.
M1514K) in ﬁve patients from four families. The
mutations had arisen de novo in all four pedigrees.
Although a second mutation was not found in any
of the ﬁve patients by sequence or dosage analysis
in leukocyte DNA, the presence of a mutation in
the regulatory regions of the gene or as a result
of a somatic event during pancreatic develop-
ment cannot be excluded. However, as histological
examination and chromosome 11p15 microsatellite
marker analysis of resected pancreas, in four and
two patients respectively, were consistent with dif-
fuse disease, we conclude that G1485E, D1506E
and M1514K are dominantly acting ABCC8 muta-
tions associated with diffuse disease and a 50%
risk of HH in future offspring.
All the ﬁve patients presented with severe HH
within the ﬁrst 3 days of life with no response to
maximum doses of diazoxide (20 mg/kg/day) and
subsequently underwent near total pancreatectomy.
This clinical presentation is very different to that
described in previous reports of dominant ABCC8
mis-sense mutations that were associated with a
milder phenotype (7, 8). The mutations identiﬁed
in our series are novel, suggesting a genotype/
phenotype correlation where different mis-sense
mutations may result in a variable severity of HH.
Pancreatic β-cell KATP channels are regulated by
intracellular nucleotides (ATP and ADP). SUR1
has two cytoplasmic nucleotide-binding domains
(NBD1 and NBD2) that sense changes in intra-
cellular [ATP]/[ADP] and transmit the signal to
the pore. Binding of MgATP to NBD2 leads to
its hydrolysis to MgADP, which then activates
the KATP channel (14). The ability of diazoxide to
activate the channel depends on the simultaneous
presence of MgATP and/or MgADP and functional
NBDs (15–17). Mutations in NBD2 can there-
fore abolish channel activation by diazoxide or
MgADP (15). This loss of activation by MgADP
on KATP channel activity when metabolism is
reduced has been reported for patients with
HH because of recessive ABCC8 mutations and
seems to be a common molecular mechanism of
HH (18, 19).
Nine of the 11 previously reported dominant
ABCC8 mutations affect residues within the NBD2
region and functional studies have shown that these
mutations signiﬁcantly diminish or completely
abolish the channels’ response to MgADP and
diazoxide (7, 8). Further studies on 10 of the
ABCC8 mutations, under simulated heterozygous
conditions, indicated that although the mutant
subunits do reduce channel function, the wild-
type ABCC8 allele is sufﬁcient to confer partial
channel response to changes in the ATP/ADP
ratio expected during glucose metabolism and to
diazoxide (8). The three mutations identiﬁed in
this series of patients are located in the NBD2
region of SUR1 and it is likely that they also
abolish the stimulatory effects of MgADP. This
hypothesis is supported by the identiﬁcation of the
same mutation, D1506E, in three individuals from
two families with diazoxide-unresponsive HH.
Our ﬁndings suggest that the clinical pre-
sentation of patients with dominant inactivating
ABCC8 mis-sense mutations is variable, ranging
from mild medically responsive to severe early
onset HH requiring a near total pancreatectomy.
The clinical presentation of patients at the time
of diagnosis cannot distinguish between reces-
sive and dominantly acting ABCC8 mutations. A
genetic diagnosis is important because ﬁnding a
586Dominant ABCC8 mutations and severe HH
de novo dominant mutation in a sporadic case
with diazoxide-unresponsive HH confers a lower
recurrence risk for future siblings compared to a
recessive mutation, but a higher risk of HH (50%)
for the next generation.
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